Jennifer L. Good - Sep 6, 2024 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
President & CEO, Director
Signature
/s/ Christopher Galletta, attorney-in-fact
Stock symbol
TRVI
Transactions as of
Sep 6, 2024
Transactions value $
-$9,707
Form type
4
Date filed
9/9/2024, 05:00 PM
Previous filing
Sep 5, 2024
Next filing
Sep 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRVI Common Stock Options Exercise $6.03K +4.22K +1.98% $1.43 218K Sep 6, 2024 Direct
transaction TRVI Common Stock Sale -$12.8K -4.22K -1.94% $3.03 213K Sep 6, 2024 Direct F1
transaction TRVI Common Stock Options Exercise $2.63K +1.84K +0.86% $1.43 215K Sep 9, 2024 Direct
transaction TRVI Common Stock Sale -$5.59K -1.84K -0.86% $3.04 213K Sep 9, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Options Exercise $0 -4.22K -69.63% $0.00 1.84K Sep 6, 2024 Common Stock 4.22K $1.43 Direct F3
transaction TRVI Stock Option (right to buy) Options Exercise $0 -1.84K -100% $0.00 0 Sep 9, 2024 Common Stock 1.84K $1.43 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.010 to $3.085 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 This option was granted on November 25, 2014. The 61,180 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018.